ARCT News and Press, Arcturus Therapeutics Ltd. From 02/28/22

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2021 Earnings Conference Call February 28, 2022, 4:30 PM ET Company Participants Joseph Payne – President and Chief Executive Officer Andy Sassine – Chief Financial Officer Deepankar Roy – Senior Director Investor Relations Co...

Arcturus Therapeutics press release (NASDAQ:ARCT): Q4 GAAP EPS of -$1.47 beats by $0.16. Revenue of $5.8M (+163.6% Y/Y) misses by $5.85M. For further details see: Arcturus Therapeutics GAAP EPS of -$1.47 beats by $0.16, revenue of $5.8M misses by $5.85M

Emergency Use Authorization (EUA) application for ARCT-154 submitted to Vietnam Ministry of Health ARCT-154 Phase 1/2 booster study data in U.S. and Singapore demonstrated 28-, and 54-fold increases in neutralizing antibody activity against SARS-CoV-2 ancestral and Omicron...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Analysis of sera from Phase 1/2 booster study demonstrates 54- and 47-fold increases in geometric mean neutralizing antibody titers against the Omicron variant at Day 29 for ARCT-154 (5 mcg) and ARCT-165 (5 mcg) respectively Arcturus Therapeutics Holdings Inc. (the “C...

Full cohort data from the ARCT-154 (5 mcg) arm of the ongoing Phase 1/2 booster study shows 30-fold increase in neutralizing antibody geometric mean concentrations against SARS-CoV-2 at Day 15 post-boost, maintained at 28-fold increase at Day 29, using a validated pseudovirus microneu...

PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new me...

Arcturus Therapeutics (NASDAQ: ARCT) , which focuses on clinical-stage messenger RNA (mRNA) medicines, saw its shares rise 16% on Thursday. The stock closed at $35.52 on Wednesday, then opened at $38 today and rose to as high as $41.15 by midmorning. The stock has a 52-week high of ...